Pinterest Ads dashboards for Healthcare / Pharma campaigns report clean CPMs and above-benchmark CTR, but neither number tells you how much of that budget actually reached a patient or caregiver rather than a non-human source. Lunio built its invalid traffic data layer specifically to answer that question, adding a verified read on traffic quality to every reported benchmark so pharma marketers can see what their spend is actually buying. Find out how much of your Pinterest Ads budget is being wasted →
Pinterest opened its pharma advertising programme in a closed alpha in 2023 and ran its first HCP (healthcare professional) campaign only in 2025, per IQVIA Digital's July 2025 account of the IQVIA/CMI Media Group collaboration. That recency means the advertiser base is still small, competition for impressions is low, and auction dynamics remain structurally favourable compared with Meta or Google for the same vertical. It also means pharma advertisers cannot use condition-based interest targeting or lead ads under Pinterest's advertising guidelines, which pushes the entire category toward awareness and consideration objectives measured on impressions and clicks rather than direct conversions.
| Campaign Type | IVT Rate (cross-industry reference) | Avg. CPC | Avg. CPM |
|---|---|---|---|
| Standard Pin Ads | 8.51% | ~$0.50 | $3–$4 |
| Video Pin Ads (autoplay) | 8.51% | $0.60–$0.90 | $3–$5 |
| Shopping Ads (Product Pins) | 8.51% | $0.70–$1.00 | $2–$4 |
| Carousel Ads | 8.51% | $0.50–$0.80 | $3–$4 |
| Idea Pin Ads | 8.51% | ~$0.50+ | $2–$5 |
The CPC and CPM figures above are cross-vertical Pinterest averages from AdBacklog's "Pinterest Ads Benchmarks Per Industry," April 2025, not Healthcare/Pharma-specific data, and the IVT rate is the global cross-industry average since no Pinterest × Healthcare/Pharma breakdown yet exists in Lunio's dataset. Pinterest is predominantly a mobile-first platform, with 450+ million monthly active users globally and the large majority of sessions on mobile devices, per Pinterest Business figures cited by Improvado, 2026, which makes mobile/desktop CPC or CPM splits less analytically meaningful for Pinterest than for Google Ads or Meta.
No published source, including Benchmarketing or AdBacklog, breaks out Pinterest CPC or CPM by device for any vertical. Given that Pinterest's traffic is overwhelmingly mobile, a device-level split would carry far less signal than it does on search-driven platforms where desktop research behaviour and mobile conversion behaviour genuinely diverge. For Healthcare / Pharma advertisers planning budget, the more useful question is not mobile versus desktop cost, but what share of mobile impressions and clicks are human at all, a question device-split reporting cannot answer on its own.
This page draws on three tiers of evidence: Benchmarketing's healthcare-specific CPM quartiles (blended observed/modelled/cited methodology, reviewed March 2026), AdBacklog's cross-vertical Pinterest benchmark table (cross-vertical proxy, not Healthcare-specific), and Lunio's global and cross-vertical IVT figures from the Lunio 2026 Global Invalid Traffic Report. Every figure above is labelled according to its actual source rather than presented as a single verified Pinterest Healthcare number. Calculate how much you're losing →
Pinterest restricts pharma advertisers to "certain" approved ad formats rather than opening the full format catalogue, which narrows optimisation choices compared with Meta or TikTok for the same vertical. What's known about format-level performance comes mostly from Publicis Health Media's alpha-phase pharma campaigns and AdBacklog's cross-vertical format data, not from Healthcare-specific Lunio figures, so the implications below focus on IVT exposure and creative strategy rather than invented cost numbers.
Standard Pin Ads (single image): IVT exposure tracks the global cross-industry average of 8.51%, since no format-specific breakdown exists. For pharma, static image pins remain a safe baseline format, and because they're optimised on impressions and pin clicks rather than any downstream conversion signal, inflated engagement here can look like creative success without any corresponding increase in website visits or HCP conversations.
Video Pin Ads, including max-width video: Publicis Health Media found that max-width video eliminated the branded/unbranded CTR gap seen in other formats and produced the highest CTR among all pharma ad formats tested, while standard-width video underperformed static image ads, per Fierce Pharma, October 2024. Video formats also carry more automated bidding exposure than static pins, since Pinterest's delivery algorithm optimises toward engagement signals like saves and autoplay completions. If a meaningful share of those signals are invalid, the algorithm learns to chase inventory that produces more of the same, a contamination loop that is structurally harder to detect on a format with no conversion tracking to validate against.
Shopping Ads (Product Pins): More relevant to OTC and wellness product advertisers than Rx pharma, given Pinterest's prohibition on lead ads for prescription drugs, OTC products, health apps, and telehealth. Where used, Shopping Ads carry the platform's lowest cross-vertical CPA among formats, per AdBacklog, April 2025, but GLP-1 and other regulated categories face additional Pinterest policy restrictions in the US and Canada that further limit format and targeting flexibility.
Carousel Ads: A useful format for patient journey storytelling across multiple condition-education panels. Carousel engagement is measured the same way as single-image pins, meaning the same impression-level and click-level IVT exposure applies without a mitigating conversion signal.
Idea Pin Ads: A multi-page, engagement-first format with no direct conversion mapping, making it the hardest format in which to distinguish genuine patient research behaviour from inflated engagement metrics, since there's no downstream outcome to check the numbers against.
Pinterest's pharma advertising programme is effectively a US and Canada story: prescription drug and OTC advertising on the platform requires prior approval and is concentrated in these two markets, with most European markets not supporting comparable prescription advertising on social platforms at all.
| Country | IVT Rate |
|---|---|
| United States | 8.44% |
| United Kingdom | 7.97% |
| Germany | 6.34% |
| France | 6.63% |
| Australia | 7.87% |
| Canada | 6.29% |
These are verified country-level IVT rates across all verticals, per Lunio's ad fraud data by country, not Pinterest-specific figures, but they're directly relevant because the US and Canada are the two markets where Pinterest pharma advertising actually runs. The US carries the highest IVT exposure of the two at 8.44%, meaning the largest and most established market for Pinterest pharma campaigns is also the one with proportionally more non-human traffic to filter out. Canada, by contrast, sits at the lowest rate in this entire table at 6.29%, which combined with Pinterest's lower pharma advertiser density there makes it a structurally more efficient market on a traffic-quality basis, even though absolute budgets will typically be smaller.
A mid-size pharma brand running a US awareness campaign on Pinterest at an industry-informed pilot scale of $500,000 annually is paying for roughly 40 million impressions at the Benchmarketing median CPM of $12.40. Applying the global cross-industry average IVT rate of 8.51%, per Lunio's 2026 Global Invalid Traffic Report, that's approximately $42,550 spent on non-human impressions and clicks in a single year. Because Pinterest's Healthcare / Pharma campaigns are almost entirely awareness and consideration models rather than transactional ones, and lead-generation/non-transactional models see 32.07% higher IVT than transactional models per Lunio's research, a more realistic modelled rate runs closer to 11%, pushing the annual waste figure toward $56,200 on the same budget. Both figures are modelled proxy estimates, not a verified Pinterest Healthcare observation, and they will shift once Pinterest-specific Healthcare/Pharma data is collected.
This pattern isn't unique to pharma. When KURU Footwear expanded from bottom-of-funnel acquisition into awareness channels, a Lunio audit found 19.85% IVT on its primary branded shopping campaign, falling to 4.38% after 90 days of protection, a 32% reduction, with branded search revenue per dollar spent rising 30% afterward. Pharma's awareness-first model on Pinterest sits in the same structural position: good-looking dashboard metrics with no downstream signal to check them against. Lunio's protection already runs on Pinterest specifically: Dutch DTC brand Sparkles.io extended Lunio across Google Ads, Bing, Meta, Pinterest, and YouTube, saving up to €548,000 in 2023 alone at a 30x return on its subscription cost.
These are modelled estimates using cross-vertical proxy rates. The only way to know what share of your specific Pinterest healthcare budget is reaching real patients is to audit the actual traffic behind your campaign metrics.
Start your free 14-day traffic audit with Lunio →
Benchmarks like a $12.40 median CPM or a CTR above the platform average are a starting point for evaluating Pinterest as a pharma channel, not a confirmation that the budget behind them is working. The gap between what Pinterest Ads Manager reports and what a real patient or caregiver actually saw is exactly where invalid traffic hides, and it hides longest in awareness campaigns with no lead ads and no prescription tracking to surface it. Lunio exists to measure that gap directly rather than leave it to inference.
Start your free 14-day traffic audit with Lunio →
No first-party Healthcare/Pharma CPC benchmark exists for Pinterest. The best available reference points combine Publicis Health Media's 75% cost-efficiency claim relative to other social platforms (Fierce Pharma, October 2024) with the Finance vertical proxy on Pinterest of $0.80 to $1.50 (AdBacklog, April 2025), together suggesting pharma CPC on Pinterest likely sits somewhere between $0.33 and $1.50 depending on targeting and format.
Publicis Health Media found that both branded and unbranded pharma campaigns exceeded Pinterest's platform CTR benchmark, with unbranded creative and max-width video performing best. But because pharma campaigns on Pinterest can't use lead ads or direct conversion tracking, CTR is often the primary success metric advertisers rely on, which also makes it the metric most vulnerable to distortion from automated pin-level engagement. A CTR that's dramatically higher than the Pinterest benchmark without a corresponding rise in outbound clicks or website engagement is worth auditing rather than celebrating.
Invalid traffic inflates impression counts against CPM budgets and inflates engagement counts against CTR, both without delivering a real patient or caregiver. For Healthcare / Pharma specifically, non-human engagement signals also feed Pinterest's automated bidding, which optimises delivery toward whatever inventory produces the most clicks and saves, invalid or not, creating a feedback loop that's invisible in the dashboard but shows up as flat or declining downstream results, such as website engagement or HCP conversations, even as reported metrics hold steady or improve.
Among verified country-level IVT rates across all verticals, per Lunio's ad fraud data by country, the US runs higher at 8.44% than most of the European markets shown, with the UK at 7.97%, France at 6.63%, and Germany at 6.34% all lower. Since Pinterest pharma advertising is effectively restricted to the US and Canada, and Canada's rate of 6.29% is the lowest in this comparison, European benchmarks are useful mainly as context rather than as a direct reference point for pharma campaigns currently running on the platform.